Literature DB >> 29246092

Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.

Gabriella A Horvath1,2, Maja Tarailo-Graovac3, Tanja Bartel4, Simone Race1, Margot I Van Allen2,5, Ingrid Blydt-Hansen2,6, Colin J Ross2,7, Wyeth W Wasserman2,3, Mary B Connolly8, Clara D M van Karnebeek2,3.   

Abstract

PAK3-related intellectual disability is caused by mutations in the gene encoding the p21-activated kinase (PAK) protein. It is characterized by mild to moderate cognitive impairment, micro/normocephaly, and a neurobehavioral phenotype characterized by short attention span, anxiety, restlessness, aggression, and self-abusive behaviors. The authors report a patient with a novel PAK3 mutation, who presented with intellectual disability, severe automutilation, and epilepsy. His magnetic resonance imaging changes were most likely secondary to lacerations from parenchymal contusions. His behavior was difficult to manage with behavior interventions or multiple medications. After finding low levels of dopamine and borderline low serotonin metabolites in the spinal fluid, treatment with low dose L-dopa/carbidopa and 5-hydroxytryptophan significantly improved his self-injurious behavior. This is the first case of PAK3-related intellectual disability presenting with severe self-injury with improvement following treatment. The patient's response to neurotransmitter replacement therapy raises the question if this treatment intervention might help other individuals suffering genetic syndromes and self-injurious behaviors.

Entities:  

Keywords:  5-hydroxytryptophan; L-dopa; cerebrospinal fluid neurotransmitters; homovanillic acid; self-injury

Mesh:

Substances:

Year:  2018        PMID: 29246092     DOI: 10.1177/0883073817740443

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  7 in total

1.  Elucidation of the Central Serotonin Metabolism Pathway in Rhesus Macaques (Macaca mulatta) with Self-injurious Behavior.

Authors:  Rachael L Cohen; Julia L Drewes; Suzanne E Queen; Zachary T Freeman; Kelly Metcalf Pate; Robert J Adams; David R Graham; Eric K Hutchinson
Journal:  Comp Med       Date:  2021-11-18       Impact factor: 1.565

2.  A pilot study on machine learning approach to delineate metabolic signatures in intellectual disability.

Authors:  Vidya Nikam; Suvidya Ranade; Naushad Shaik Mohammad; Mohan Kulkarni
Journal:  Int J Dev Disabil       Date:  2019-04-15

Review 3.  A novel PAK3 pathogenic variant identified in two siblings from a Japanese family with X-linked intellectual disability: case report and review of the literature.

Authors:  Aritoshi Iida; Kyoko Takano; Eri Takeshita; Chihiro Abe-Hatano; Shinichi Hirabayashi; Yuji Inaba; Shunichi Kosugi; Yoichiro Kamatani; Yukihide Momozawa; Michiaki Kubo; Eiji Nakagawa; Ken Inoue; Yu-Ichi Goto
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-12-13

4.  Novel PAK3 gene missense variant associated with two Chinese siblings with intellectual disability: a case report.

Authors:  Yanyan Qian; Bingbing Wu; Yulan Lu; Wenhao Zhou; Sujuan Wang; Huijun Wang
Journal:  BMC Med Genet       Date:  2020-02-12       Impact factor: 2.103

Review 5.  Treatable inherited metabolic disorders causing intellectual disability: 2021 review and digital app.

Authors:  Eva M M Hoytema van Konijnenburg; Saskia B Wortmann; Marina J Koelewijn; Laura A Tseng; Roderick Houben; Sylvia Stöckler-Ipsiroglu; Carlos R Ferreira; Clara D M van Karnebeek
Journal:  Orphanet J Rare Dis       Date:  2021-04-12       Impact factor: 4.123

6.  Clinical and Molecular Aspects of the Neurodevelopmental Disorder Associated with PAK3 Perturbation.

Authors:  Giulia Pascolini; Federica Gaudioso; Chiara Passarelli; Antonio Novelli; Niccolò Di Giosaffatte; Silvia Majore; Paola Grammatico
Journal:  J Mol Neurosci       Date:  2021-07-05       Impact factor: 3.444

7.  Secondary biogenic amine deficiencies: genetic etiology, therapeutic interventions, and clinical effects.

Authors:  Maja Tarailo-Graovac; Gabriella A Horvath; Clara D van Karnebeek; Ingrid Blydt-Hansen; Allison M Matthews; Vladimir Avramovic; Magda Price; Britt Drogemoller; Casper Shyr; Jessica Lee; Jill Mwenifumbo; Aisha Ghani; Sylvia Stockler; Jan M Friedman; Anna Lehman; Colin J Ross; Wyeth W Wasserman
Journal:  Neurogenetics       Date:  2021-07-02       Impact factor: 2.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.